Exhibit 99.2

B E L I T E B I O / 1 December 1, 2025, 8:00 a.m. ET Nasdaq: BLTE Phase 3 DRAGON Trial in Stargardt Disease Topline Results

B E L I T E B I O / 2 This presentation (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities of Belite Bio, Inc. (“Belite Bio”) from any investor or in any jurisdiction in which such an offer or solicitation is not authorized or would be unlawful. No shares or other securities of Belite Bio are being offered to the public by means of this presentation. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This presentation is being given on the condition that it is for use by the recipient for information purposes and to evaluate Belite Bio and the proposed offering of securities of Belite Bio and for no other purpose. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Any statements in this presentation about Belite Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about the strategy, operations and future expectations and plans and prospects for Belite Bio, and any other statements containing the words “expect,” “intend”, “plan,” “predict,” “target,” “will,” “could,” “should,” “continue,” and similar expressions. This presentation contains forward-looking statements, including statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; Belite Bio's ability to achieve commercial success for its drug candidates, if approved; Belite Bio's ability to obtain and maintain protection of intellectual property for its technology and drugs; Belite Bio's reliance on third parties to conduct drug development, manufacturing and other services; Belite Bio's limited operating history and Belite Bio's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; and Belite Bio's ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, as well as those risks more fully discussed in the “Risk Factors” section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Market data and industry information used throughout this presentation are based on the knowledge of the industry and the good faith estimates of Belite Bio’s management. Belite Bio also relied, to the extent available, upon management’s review of independent industry surveys and publications and other publicly available information prepared by a number of third-party sources. All of the market data and industry information used in this presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Although the Belite Bio believes that these sources are reliable, it cannot guarantee the accuracy or completeness of, and has not independently conducted verification of the relevant market data and industry information used herein. While Belite Bio believes the estimated market position, market opportunity and market size information included in this presentation are generally reliable, such information, which is derived in part from the management’s estimates and beliefs, is inherently uncertain and imprecise. No representations or warranties are made by Belite Bio or any of its affiliates as to the accuracy of any such statements or projections. Projections, assumptions and estimates of our future performance and the future performance of the industry in which Belite Bio operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described above. These and other factors could cause results to differ materially from those expressed in our estimates and beliefs and in the estimates prepared by independent parties. Forward-Looking Statements and Legal Disclaimer

B E L I T E B I O / 3 Today’s Speakers Tom Lin, MMED, PhD, MBA Chairman & Chief Executive Officer Nathan Mata, PhD Chief Strategy Officer Hendrik Scholl, MD, MA Chief Medical Officer Prof Leopold Schmetterer, PhD Prof Ruifang (Helen) Sui, MD, PhD • Consultant Ophthalmologist at Moorfields Eye Hospital in the Departments of Medical Retina, Inherited Eye Disease and Paediatric Ophthalmology • Professor of Ophthalmology at the UCL Institute of Ophthalmology Prof Michel Michaelides, BSc MB BS MD(Res) FRCOphth FACS • Head of Ocular Imaging and Scientific Director at Singapore Eye Research Institute • Professor at the Nanyang Technological University • DSMB Chair of the DRAGON study • Professor, Director of the Department of Ophthalmology at Peking Union Medical College Hospital • Vice President of the Chinese Medical Doctor Association Ophthalmology Committee & Counsellor of the Chinese Ophthalmology Genetics Alliance Belite Management Key Opinion Leaders

B E L I T E B I O / 4 Agenda Stargardt Disease Overview Study Design Efficacy Results Safety Results Summary KOL Panel Discussion Q&A

B E L I T E B I O / 5 Stargardt Disease Overview

B E L I T E B I O / 6 Stargardt Disease Overview Stargardt disease (STGD1) and/or ABCA4-associated retinal dystrophy is a rare and progressive eye disease leading to legal blindness in almost all cases. There is no approved treatment for Stargardt disease • Autosomal recessive mutations in the ABCA4 gene, impairing retinoid transport and leading to toxic bisretinoid buildup in the retinal pigment epithelium (RPE) • Bisretinoid accumulation manifests as yellowish flecks underneath the retina and causes oxidative stress, toxicity, and eventually RPE cell death • RPE damage leads to secondary degeneration of macular photoreceptors • Progressive macular atrophy and retinal degeneration • Gradual central vision loss in both eyes, often starting in childhood or early adulthood • Blurry or distorted central vision • Central blind spots (scotomas) • Photophobia and delayed dark adaptation • Impaired color vision • Difficulty with detailed tasks like reading or recognizing faces • Peripheral vision preserved in the majority of cases • Challenges with reading, using screens, and recognizing faces, harming education and work • Typically, inability to drive, reducing mobility and independence • Restrictions in sports, leisure, and simple tasks like avoiding trips • Social struggles, including interactions, relationships, and events • Emotional effects like frustration, worry, anger, and depression • Career changes or job loss, affecting finances and productivity Pathophysiological Changes Key Symptoms Impact on Activities of Daily Living

B E L I T E B I O / 7 Estimated Patient Population Sizes of Stargardt Disease Mata NL, Weng S, Michaelides M, Charbel Issa P, Quinodoz M, Rivolta C, Scholl HPN. Bisretinoids as a Source of Early Photoreceptor Pathology in Stargardt Disease. Ophthalmic Res. 2025 Nov 7:1-28. doi: 10.1159/000549368. Europe Australia China Japan United States GnomAD Ethnicity European European East Asian East Asian Mixed Population (N) 742,000,000 26,640,000 1,411,000,000 124,500,000 334,900,000 STGD1 Patients (N) High Estimate 115,345 4,141 122,135 10,777 59,235 Low Estimate 95,517 3,429 94,940 8,377 46,767

B E L I T E B I O / 8 Standard of Care Fundus Autofluorescence Imaging in Stargardt Disease • 37-year-old male patient • Compound heterozygous for mutations in ABCA4 • Visual acuity (baseline): 20/40 • Visual acuity (at 4Y): 20/80 Atrophy Progression over 4 Years

B E L I T E B I O / 9 Study Design

B E L I T E B I O / 1 0 DRAGON Clinical Trial Design in Stargardt Disease Reduction in atrophic lesion growth rate as measured by fundus autofluorescence imaging is the FDA’s accepted primary endpoint in Stargardt disease and geographic atrophy secondary to age-related macular degeneration Study Design DRAGON Design Key Inclusion Criteria • Clinical diagnosis of Stargardt disease • 12-20 years old • ≥1 mutation identified in the ABCA4 gene • Atrophic lesion size (DDAF) within 3 disc areas (7.62 mm2 ) • BCVA of 20/200 or better N=104 Randomized 2:1 Placebo n=35 Treatment n=69 Primary Measures • Slowing of atrophic lesion growth (DDAF) • Safety and tolerability Secondary Measures • DAF • BCVA • SD-OCT • Microperimetry Phase 3 Trial 2-Year Duration Double-blinded, global trial of oral Tinlarebant 5mg/day DDAF = Definitely Decreased Autofluorescence; DAF = Decreased Autofluorescence; BCVA = Best-Corrected Visual Acuity; SD-OCT = Spectral-Domain Optical Coherence Tomography

B E L I T E B I O / 1 1 DRAGON Baseline DDAF Lesion Size Study Design Tinlarebant (5mg) Placebo N 63 33 Mean 2.251 2.418 SD 2.0871 2.2050 Median 1.546 1.822 Min – Max 0.07 – 7.02 0.06 – 7.29 Baseline DDAF (mm2 ) – Study Eye Baseline DDAF (mm2 ) – Fellow Eye Tinlarebant (5mg) Placebo N 57 29 Mean 2.511 3.020 SD 2.0263 2.3029 Median 1.946 2.287 Min - Max 0.07 – 7.55 0.25 – 7.54

B E L I T E B I O / 1 2 Efficacy Results

B E L I T E B I O / 1 3 Daily dosing of 5 mg/day Tinlarebant led to a sustained 80% reduction of RPB4 and RPB4 levels returned to 84 % of the baseline value at the End of Study (EOS) Biomarker: RBP4 - Percent Reduction from Baseline PD Set N=92 Efficacy Results 70% Reduction Target Tinlarebant Treatment Led to 80% Reduction in RPB4, Well Above Goal of 70%* * In a prior study of a surrogate RBP4 antagonist (fenretinide) in patients with Geographic Atrophy, an RBP4 reduction of ≥70% was associated with a statistically significant slowing of lesion growth [Mata et al., Retina. 2013; 33(3): 498-507.]

B E L I T E B I O / 1 4 DDAF Represents Well-demarcated Areas of Complete RPE Loss & Grows Predictably, Making it an Approvable Primary Endpoint • DDAF (definitely decreased autofluorescence): level of darkness close to 100% (at least 90%) in reference to the ONH • QDAF (questionably decreased autofluorescence): between 50% and 90% darkness • DAF (decreased autofluorescence): the sum of DDAF and QDAF DDAF QDAF DDAF QDAF ONH Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, Birch DG, Bernstein PS, Michaelides M, Traboulsi EI, Zrenner E, Sadda S, Ervin AM, West S, Scholl HPN; Progression of Stargardt Disease Study Group (2016) The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1. Ophthalmology. 123: 817-28. DAF DDAF+QDAF DAF DDAF+QDAF

B E L I T E B I O / 1 5 DDAF Progression Rate in Stargardt Overall DDAF growth rate in the ProgStar cohort over 24 months: 0.74 mm2/year (confidence interval: 0.64 - 0.85 mm2/year) Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study Strauss RW, Ho A, Jha A, Fujinami K, Michaelides M, Cideciyan AV, Audo I, Birch DG, Sadda S, Ip M, West S, Schönbach EM, Kong X, Scholl HPN; ProgStar Study Group (2023) The progression of Stargardt Disease as determined by fundus autofluorescence over a 24-month period (ProgStar Report No. 17). Am J Ophthalmol. 250: 157-170.

B E L I T E B I O / 1 6 Primary Endpoint: DDAF in the Study Eye (Change from Baseline) • Annualized rate of lesion growth in the aggregate area of atrophy (DDAF) from baseline as assessed by fundus autofluorescence imaging at Month 25. • Data is shown for the modified full analysis set (mFAS) which consists of all subjects who were randomly assigned to receive study drug and have received at least one dose of study medication. In addition, the mFAS subjects must have a defined DDAF lesion meeting the eligibility criteria at baseline and have at least one post baseline assessment. • Data analysis used a Mixed Model for Repeated Measures (MMRM) measuring change from baseline in DDAF in the study eye and including terms for treatment, visit, treatment*visit interaction, baseline focality of lesions, and baseline DDAF lesion size. • The Statistical Analysis Plan (SAP) specified an unstructured covariance matrix for the MMRM. The CRO also performed a post-hoc analysis using a first-order autoregressive covariance matrix to account for the longitudinal nature of the data while maintaining model stability in a relatively small sample such as in the DRAGON trial. Efficacy Results

B E L I T E B I O / 1 7 Applying an unstructured covariance matrix, the treatment effect size was 35.7% compared to placebo and yielded a p-value of P = 0.0033 With a first-order autoregressive covariance matrix, the treatment effect size remained consistent (35.4%) with P <0.0001 DDAF lesion growth was slowed to 0.38 mm2/year vs. 0.59 mm2/year for placebo and 0.74 mm2/year observed in ProgStar Primary Endpoint: DDAF Change from Baseline (Study Eye) mFAS N = 96 Efficacy Results Primary Endpoint Showed a Statistically Significant & Clinically Meaningful Outcome

B E L I T E B I O / 1 8 Tinlarebant slowed DDAF lesion growth in the fellow eye by 33.6% compared to placebo (P = 0.041) Primary Endpoint: DDAF Change from Baseline (Fellow Eye) mFAS N = 95 Efficacy Results A Statistically Significant Treatment Effect Was Also Observed in the Fellow Eye for the Primary Endpoint

B E L I T E B I O / 1 9 Tinlarebant slowed DAF lesion growth by 33.7% compared to placebo (P = 0.027) Key Secondary Endpoint: DAF Change from Baseline (Study Eye) mFAS N = 96 Efficacy Results Tinlarebant Slowed DAF Lesion Growth, the Key Secondary Endpoint, in the Study Eye by 33.7%

B E L I T E B I O / 2 0 Tinlarebant slowed DAF lesion growth in the fellow eye by 32.7% compared to placebo (P = 0.017) Key Secondary Endpoint: DAF Change from Baseline (Fellow Eye) mFAS N = 94 Efficacy Results Tinlarebant Slowed DAF Lesion Growth, the Key Secondary Endpoint, also in the Fellow Eye by 32.7%

B E L I T E B I O / 2 1 As Expected, BCVA in Study Eye Did Not Show Any Significant Change Tinlarebant Placebo BCVA at Baseline 39.9 39.4 BCVA at EOS 39.7 40.0 • The overall change of visual acuity was minimal over the period of 24 months in both treatment groups • Test–retest variability for ETDRS change scores in Stargardt disease are known to yield a repeatability coefficient ≈ 8 letters (1) • Such minor changes in average visual acuity over two years are in line with the natural history of Stargardt disease and were observed in the ProgStar Study (1) Parker MA, Choi D, Erker LR, Pennesi ME, Yang P, Chegarnov EN, Steinkamp PN, Schlechter CL, Dhaenens CM, Mohand-Said S, Audo I, Sahel J, Weleber RG, Wilson DJ. Test-Retest Variability of Functional and Structural Parameters in Patients with Stargardt Disease Participating in the SAR422459 Gene Therapy Trial. Transl Vis Sci Technol. 2016 Oct 1;5(5):10. Efficacy Results

B E L I T E B I O / 2 2 ProgStar: Visual Acuity Change over 24 Months Prospective Cohort (N=434) • Overall rate of BCVA loss was 0.55 letters/year over two years • BCVA of eyes with baseline BCVA between 20/70 and 20/200 declined at a rate of 0.6 letters/year Kong X, Fujinami K, Strauss RW, Munoz B, West SK, Cideciyan AV, Michaelides M, Sahel JA, Ahmed M, Ervin AM, Schönbach EM, Cheetham JK, Scholl HPN; ProgStar Study Group (2018) Visual Acuity Change over 24 Months and its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Report Number 10. JAMA Ophthalmol. 136: 920-928.

B E L I T E B I O / 2 3 Safety Results

B E L I T E B I O / 2 4 Tinlarebant Demonstrated a Well Tolerated Safety Profile Safety Set N = 104 Category Tinlarebant 5mg (N=69) Placebo (N=35) TEAE 59 (85.5%) 27 (77.1%) Severe TEAE 2 (2.9%) 1 (2.9%) Serious TEAE 2 (2.9%) 4 (11.4%) Study Drug-Related TEAE 14 (20.3%) 4 (11.4%) Study Drug-Related Serious TEAE 0 (0.0%) 0 (0.0%) TEAE Leading to Study Drug Discontinuation 0 (0.0%) 0 (0.0%) TEAE Leading to Study Discontinuation 0 (0.0%) 0 (0.0%) TEAE Leading to Death 0 (0.0%) 0 (0.0%) • Total of 6 serious adverse events (SAEs) reported in the study – all events were non-ocular, with 4 assessed as unrelated and 2 assessed as unlikely related to the study treatment • Most reported Non-Ocular adverse events (AEs): Nasopharyngitis (all cases were assessed as unrelated/unlikely related to treatment), Headache, and Acne – most events were mild and resolved during the study period Subjects Who Experienced at Least One Non-Ocular Treatment-Emergent Adverse Events (TEAE), N / (%) Safety Results

B E L I T E B I O / 2 5 The Majority of Ocular Adverse Events was Mild Safety Set N = 104 Category Tinlarebant 5mg (N=69) Placebo (N=35) TEAE 53 (76.8%) 8 (22.9%) Severe TEAE 2 (2.9%) 0 (0.0%) Serious TEAE 0 (0.0%) 0 (0.0%) Study Drug-Related TEAE 49 (71.0%) 8 (22.9%) Study Drug-Related Serious TEAE 0 (0.0%) 0 (0.0%) TEAE Leading to Study Drug Discontinuation 4 (5.8%) 0 (0.0%) TEAE Leading to Study Discontinuation 2 (2.9%) 0 (0.0%) TEAE Leading to Death 0 (0.0%) 0 (0.0%) • Most reported Ocular AEs: Xanthopsia, Delayed dark adaptation, and Night Vision Impairment • The majority of the events were mild, and most resolved while on study • There were no serious ocular TEAEs – 4 TEAEs lead to study drug discontinuation and 2 TEAEs lead to study discontinuation Subjects Who Experience at Least One Ocular TEAE, N / (%) Safety Results

B E L I T E B I O / 2 6 Summary

B E L I T E B I O / 2 7 Summary of Results of the DRAGON Trial • The DRAGON trial met its primary endpoint: A highly statistically significant slowing in DDAF lesion growth was observed in subjects treated with 5 mg/day oral Tinlarebant as compared to placebo • The treatment effect was 36% and must be considered clinically meaningful • The observed treatment effect was supported by the fellow eye data and the key secondary endpoint: a reduction of DAF area growth • The change in best-corrected visual acuity was minimal in both the treatment and the placebo group – and is in-line with natural history data • The biomarker of tinlarebant treatment, RBP4 reduction, showed a sustained 80% reduction with very little variability • Tinlarebant (5 mg p.o., daily) was safe and well tolerated in adolescent STGD1 patients Summary

B E L I T E B I O / 2 8 Tinlarebant has the Potential to be the First-Ever Approved Treatment for Stargardt Disease • First-ever oral therapy in a retinal degenerative disease to demonstrate a clinically meaningful slowdown of neurodegeneration • 36% reduction in DDAF lesion growth rate, representing a robust and reproducible treatment effect in Stargardt disease • Excellent safety and tolerability profile across two years of treatment • Addresses the root pathogenic mechanism (bisretinoid accumulation), offering a rational, disease-modifying approach where no approved therapies currently exist • Broad applicability across disease stages, from early ABCA4-mediated changes to more advanced atrophy • Personal clinical impact: After >20 years caring for these patients, this represents a true game changer – a therapy I would confidently offer to all my Stargardt patients* Conclusions * Quoted from Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio, based on his personal experience as an ophthalmologist treating STGD1 patients.

KOL Panel Discussion For more info please visit: www.belitebio.com

Q&A For more info please visit: www.belitebio.com